Changes in Beneficial Ownership · 4
Scholar Rock Holding Corporation
SRRKNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-10272026_111033.xml
Filing details
- Report period
- 2026-10-23
- Issuer
- Scholar Rock Holding Corp
- Issuer CIK
- 0001727196
- Trading symbol
- SRRK
Reporting owner 1
- Name
- AKKARAJU SRINIVAS
- Reporting owner CIK
- 0001253170
- Relationship
- Director
- Address
- 628 MIDDLEFIELD ROAD, PALO ALTO, CA, 94301
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-23 | P · Form 4 | 47,000 | A | 41.31[F1] | 6,331,029[F2] | I | By Samsara BioCapital, L.P.[F3] |
| Common Stock | 2026-10-23 | P · Form 4 | 94,000 | A | 41.31[F1] | 624,038 | I | By Samsara Opportunity Fund, L.P.[F4] |
| Common Stock | 2026-10-23 | P · Form 4 | 500 | A | 41.82[F5] | 6,331,529 | I | By Samsara BioCapital, L.P.[F3] |
| Common Stock | 2026-10-23 | P · Form 4 | 1,000 | A | 41.82[F5] | 625,038 | I | By Samsara Opportunity Fund, L.P.[F4] |
| Common Stock | 2026-10-26 | P · Form 4 | 48,988 | A | 41.59[F6] | 6,380,517 | I | By Samsara BioCapital, L.P.[F3] |
| Common Stock | 2026-10-26 | P · Form 4 | 97,982 | A | 41.59[F6] | 723,020 | I | By Samsara Opportunity Fund, L.P.[F4] |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Common Stock | 27,971 | D |
Table key
- D
- Direct
Footnotes
- F1
- The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $40.77 to $41.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.↩ 1↩ 2
- F2
- The shares held by Samsara BioCapital LP ("Samsara LP") prior to the reported transaction reflect the disposition of 83,585 shares in which the Reporting Person had no pecuniary interest. The disposition of such shares by Samsara LP did not involve a change in the Reporting Person's beneficial ownership of such shares and, accordingly, was exempt from reporting under Section 16.↩ 1
- F3
- Securities are directly held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.↩ 1↩ 2↩ 3
- F4
- Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.↩ 1↩ 2↩ 3
- F5
- The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $41.78 to $41.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.↩ 1↩ 2
- F6
- The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $41.15 to $41.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.↩ 1↩ 2
Signature 1
- Signed
- /s/ Srinivas Akkaraju
- Date
- 2026-10-27
Company context
Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Scholar Rock intends to commercialize ISEMBYLD (apitegromab-mstn) globally, beginning in the U.S. for individuals living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.